Baseline characteristics and follow-up of 87 patients with relapsing-remitting multiple sclerosis treated with alemtuzumab
| Alemtuzumab-treated patients | |
|---|---|
| n | 87 |
| Gender (n, % female) | 61 (70%) |
| Mean age (±SD) at first treatment in years (range) | 33.0 (±8) (18–49) |
| Baseline EDSS, mean (±SD), median (range) | 3·8 (±1.94) 3.5 (0–8.0) |
| Mean annualised relapse rate over 2 years pretreatment | 1.78 (±0.82) |
| Median disease duration in months at treatment (range) | 36 (5–144) |
| Prior disease-modifying therapy | n=34 (39%) |
| β-interferon | 31 (35.6%) |
| Glatiramer acetate | 7 (8%) |
| Mitoxantrone | 4 (4.6%) |
| Azathioprine | 2 (2.3%) |
EDSS, Expanded Disability Status Scale.